Inflammatory bowel disease and prostate cancer risk: a two-sample Mendelian randomization analysis

Area of Science:

• Gastroenterology
• Oncology
• Genetic Epidemiology

Background:

• Observational studies suggest a link between inflammatory bowel disease (IBD) and prostate cancer (PCa).
• Causality between IBD and PCa remains uncertain.
• Mendelian randomization (MR) offers a method to assess genetic causality.

Purpose of the Study:

• To evaluate the potential causal effect of inflammatory bowel disease (IBD) on prostate cancer (PCa) risk.
• To differentiate between association and causation using genetic data.
• To analyze the specific roles of Crohn's disease (CD) and ulcerative colitis (UC) in PCa development.

Main Methods:

• Two-sample Mendelian randomization (MR) analysis utilizing public genome-wide association studies (GWAS) data.
• Selection of instrumental variables (IVs) based on established MR assumptions.
• Primary analysis using the inverse-variance weighted (IVW) method, with complementary analyses including MR-Egger regression, Weighted Median, Simple Mode, Weighted Mode, and MR-PRESSO.

Main Results:

• Genetically predicted inflammatory bowel disease (IBD) showed no statistically significant causal effect on prostate cancer (PCa) risk (IVW P > 0.05).
• No significant causal relationship was detected for Crohn's disease (CD) or ulcerative colitis (UC) with prostate cancer (PCa) (IVW P > 0.05).
• Results from complementary MR methods corroborated the findings from the IVW analysis.

Conclusions:

• The study provides no evidence to support a causal association between inflammatory bowel disease (IBD) and prostate cancer (PCa).
• These findings contrast with previous observational studies suggesting a link.
• The genetic analysis indicates that IBD is unlikely to be a causal factor for PCa.